| Outcome Measures: |
Primary: Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF]), Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. If no Week 12 measurement was available, the last available post-baseline measurement obtained on or after Day 23 was used regardless of rescue medication. Measurements were obtained during radomization visit, and Week 12 in the double-blind period by a central laboratory., From Baseline to Week 12 | Secondary: Adjusted Mean Change From Baseline in 24-Hour Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF]), Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Measurements were obtained during lead-in, and Week 12 in the double-blind period., From Baseline to Week 12|Adjusted Mean Change From Baseline in Daytime (0900 to 2100 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF]), Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Measurements were obtained during lead-in, and Week 12 in the double-blind period., From Baseline to Week 12|Adjusted Mean Change From Baseline in Nighttime (0100 to 0600 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF]), Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Measurements were obtained during lead-in, and Week 12 in the double-blind period., From Baseline to Week 12
|
| Locations: |
Advanced Clinical Res Inst, Anaheim, California, 92801, United States|Torrance Clinical Research, Lomita, California, 90717, United States|Elite Research Institute, Miami, Florida, 33169, United States|Compass Research, Llc, Orlando, Florida, 32806, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|University Of Michigan, Ann Arbor, Michigan, 48106, United States|Prism Research, St. Paul, Minnesota, 55114, United States|Memorial Hospital Of Rhode Island, Pawtucket, Rhode Island, 02860, United States|Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, 53295, United States|Local Institution, Toronto, Ontario, M4G 3E8, Canada|Local Institution, Laval, Quebec, H7T 2P5, Canada|Local Institution, Groningen, 9713 GZ, Netherlands
|
